PURPOSE: Phase I dose-escalation study to determine the toxicity and maximum tolerated dose (MTD) of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein 90 (Hsp90) inhibitor, administered on a twice weekly schedule in patients with advanced cancer. EXPERIMENTAL DESIGN: 17-DMAG was administered as a 1- to 2-h infusion twice weekly in 4-week cycles. An accelerated titration design was followed until toxicity was observed, at which point standard dose-escalation proceeded. MTD was defined as the dose at which no more than one of the six patients experienced a dose-limiting toxicity (DLT). Pharmacokinetics were assessed, and Hsp70 mRNA, whose gene product is a chaperone previously shown to be upregulated following the inhibition of Hsp90, was measured in peripheral blood mononuclear cells (PBMCs). RESULTS: A total of 31 patients received 92 courses of treatment. The MTD was 21mg/m(2)/d; 20 patients were enrolled at this dose level. Nine patients had stable disease for a median of 4 (range 2-22) months. Both C(max) and AUC increased proportionally with dose. The most common toxicities were grade 1 or 2 fatigue, anorexia, nausea, blurred vision and musculoskeletal pain. DLTs were peripheral neuropathy and renal dysfunction. Expression of Hsp70 mRNA in PBMCs was highly variable. CONCLUSION: Twice-weekly i.v. infusion of 17-DMAG is well tolerated, and combination phase I studies are warranted. Published by Elsevier Ltd.
PURPOSE: Phase I dose-escalation study to determine the toxicity and maximum tolerated dose (MTD) of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein 90 (Hsp90) inhibitor, administered on a twice weekly schedule in patients with advanced cancer. EXPERIMENTAL DESIGN:17-DMAG was administered as a 1- to 2-h infusion twice weekly in 4-week cycles. An accelerated titration design was followed until toxicity was observed, at which point standard dose-escalation proceeded. MTD was defined as the dose at which no more than one of the six patients experienced a dose-limiting toxicity (DLT). Pharmacokinetics were assessed, and Hsp70 mRNA, whose gene product is a chaperone previously shown to be upregulated following the inhibition of Hsp90, was measured in peripheral blood mononuclear cells (PBMCs). RESULTS: A total of 31 patients received 92 courses of treatment. The MTD was 21mg/m(2)/d; 20 patients were enrolled at this dose level. Nine patients had stable disease for a median of 4 (range 2-22) months. Both C(max) and AUC increased proportionally with dose. The most common toxicities were grade 1 or 2 fatigue, anorexia, nausea, blurred vision and musculoskeletal pain. DLTs were peripheral neuropathy and renal dysfunction. Expression of Hsp70 mRNA in PBMCs was highly variable. CONCLUSION: Twice-weekly i.v. infusion of 17-DMAG is well tolerated, and combination phase I studies are warranted. Published by Elsevier Ltd.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: T W Schulte; M V Blagosklonny; L Romanova; J F Mushinski; B P Monia; J F Johnston; P Nguyen; J Trepel; L M Neckers Journal: Mol Cell Biol Date: 1996-10 Impact factor: 4.272
Authors: Takrima Sadikot; Megan Swink; Jeffery D Eskew; Douglas Brown; Huiping Zhao; Bhaskar R Kusuma; Roger A Rajewski; Brian S J Blagg; Robert L Matts; Jeffrey M Holzbeierlein; George A Vielhauer Journal: Assay Drug Dev Technol Date: 2013-10-15 Impact factor: 1.738
Authors: Dianrong Li; Tao Xu; Yang Cao; Huayi Wang; Lin Li; She Chen; Xiaodong Wang; Zhirong Shen Journal: Proc Natl Acad Sci U S A Date: 2015-04-07 Impact factor: 11.205
Authors: Giovanna Speranza; Larry Anderson; Alice P Chen; Khanh Do; Michelle Eugeni; Marcie Weil; Larry Rubinstein; Eva Majerova; Jerry Collins; Yvonne Horneffer; Lamin Juwara; Jennifer Zlott; Rachel Bishop; Barbara A Conley; Howard Streicher; Joseph Tomaszewski; James H Doroshow; Shivaani Kummar Journal: Invest New Drugs Date: 2017-08-12 Impact factor: 3.850
Authors: Amanda J Walker; Sara R Alcorn; Amol K Narang; Katriana M Nugent; Aaron T Wild; Joseph M Herman; Phuoc T Tran Journal: Curr Probl Cancer Date: 2013-10-05 Impact factor: 3.187
Authors: Yuval Samuni; Hisanari Ishii; Fuminori Hyodo; Uri Samuni; Murali C Krishna; Sara Goldstein; James B Mitchell Journal: Free Radic Biol Med Date: 2010-03-06 Impact factor: 7.376
Authors: Damien Montamat-Sicotte; Ludivine C Litzler; Cecilia Abreu; Shiva Safavi; Astrid Zahn; Alexandre Orthwein; Markus Müschen; Pablo Oppezzo; Denise P Muñoz; Javier M Di Noia Journal: Eur J Immunol Date: 2015-05-18 Impact factor: 5.532